United States

Profile: Albany Molecular Research Inc (AMRI.O)

AMRI.O on Nasdaq

20 Jul 2017
Change (% chg)

$-0.01 (-0.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Albany Molecular Research, Inc., incorporated on August 6, 1998, is a contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. The Company supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs, as well as research, development and manufacturing for the agrochemical and other industries.

DDS Segment

The Company's DDS segment offers a portfolio of services from target and lead identification tools to investigational new drug (IND) enabling activities. The IND includes drug lead discovery, library design and synthesis, synthetic and medicinal chemistry, in vitro biology and pharmacology, lead optimization, chemical development, drug metabolism and pharmacokinetics, analytical testing services and small-scale commercial manufacturing. Its services and solutions consist of chemistry library design and synthesis, high throughput and high content screening (HTS), medicinal chemistry, biology and pharmacology, including a suite of drug metabolism and pharmacokinetics that includes biotransformation and biocatalysis capabilities. It provides analytical chemistry and testing services for drug discovery, pharmaceutical development and manufacturing.

API Segment

The Company's API segment manufacturing facilities are situated in a range of locations in the United States, Europe and Asia. These locations are integrated with the Company's pharmaceutical development services. Its locations provide customer solutions and enable the transfer of pre-clinical, clinical and commercial APIs from small-scale to large-scale production. It provides chemical synthesis and manufacturing services for its customers in accordance with Current Good Manufacturing Practice (cGMP) regulations. As of December 31, 2016, its portfolio consisted of over 240 intermediates and APIs. Its portfolio is classified as proprietary API for which it has a long-term development and/or supply relationship with a customer; and generic or non-proprietary API which it develops and license and supply to customers in return for manufacturing revenue and, for certain products, royalty payments or a percentage of the profits on sales of commercialized drug products using those API.

DP Segment

The Company's DP segment provide facilities and capabilities to deliver integrated pharmaceutical drug development programs and services, including process research and development, pre-formulation and formulation development, good laboratory practice (GLP) bio analytical and separation sciences. Working in close collaboration with its established chemical synthesis, analytical development, pre-formulation and testing groups, the Company offers formulation development services for dosage forms, including solid dosage, solution, suspension, topicals, injectables, opthalmics, cGMP early clinical phase capsules filling and cGMP early clinical powder in bottle for solution and suspension. It also provides cGMP contract manufacturing services in sterile syringe, opthalmics and vial filling using technologies including lyophilization. It provides services for both small molecule drug products and biologicals, from small batch manufacturing to commercial scale.

FC Segment

The Company's FC segment provides lab to commercial scale synthesis of reagents. The Company also provides compounds to the pharmaceutical, agrochemical, detergent and cosmetics industries.

Company Address

Albany Molecular Research Inc

21 Corporate Cir,
PO Box 15098
ALBANY   NY   12203-5154
P: +1518.4640279
F: +1302.6555049

Company Web Links